Zabedosertib

DB18767InvestigationalSmall molecule

Zabedosertib: Overview.

Chemical structure of Zabedosertib
Formula / weight
C20H21F3N4O4S · 470.47 g/mol (avg)
Also known as
2-pyridinecarboxamide, n-(6-(1-hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2h-indazol-5-yl)-6-(trifluoromethyl)- · N-(6-(1-hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2h-indazol-5-yl)-6-(trifluoromethyl)-2-pyridinecarboxamide · N-(6-(2-hydroxypropan-2-yl)-2-(2-(methanesulfonyl)ethyl)- 2h-indazol-5-yl)-6-(trifluoromethyl)pyridine-2- carboxamide
Code names
BAY-1834845

Resolves to

Compound
UNIIN1GRK350ZMCAS1931994-81-8
Structure
InChIKeyOQAMEEFUUFJZRS-UHFFFAOYSA-NSMILESCC(C)(O)C1=CC2=NN(CCS(C)(=O)=O)C=C2C=C1NC(=O)C1=CC=CC(=N1)C(F)(F)F
Targets
Q9NWZ3IRAK4

What you can answer from here — as of September 26, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with Zabedosertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In